LB5001: BRUIN CLL-322: Fixed-duration pirtobrutinib plus venetoclax-rituximab outperforms venetoclax plus rituximab in patients with R/R CLL

ASH 2025

Leukemia

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Leukemia

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

J Clin Oncol

Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T

doi: 10.1200/JCO-25-02380

ASH 2025

Lymphoma

BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

EHA 2026

Leukemia

CLL14: Final 9-year analysis confirms long-term efficacy of one-year fixed-duration venetoclax plus obinutuzumab in previously untreated CLL

ASH 2025

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

Leukemia

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

Br J Haematol

Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L

doi: 10.1111/bjh.70334

Leukemia

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

J Clin Oncol

Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM

doi: 10.1200/JCO-25-00166

ASH 2025

Leukemia

AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

Lymphoma

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial

Blood

Sharman JP, Laurenti L, Ferrant EF, Casado Montero LF, Mulligan SP, Harrup RA, Opat SS, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F

doi: 10.1182/blood.2025030630

Related content

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

CLL14: Final 9-year analysis confirms long-term efficacy of one-year fixed-duration venetoclax plus obinutuzumab in previously untreated CLL

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial